Eosinophilic asthma is a more severe subtype of asthma. Treatment options include inhaled and oral corticosteroids, leukotriene modifiers, and biologics. Eosinophilic asthma is a subtype of asthma ...

Eosinophilic asthma is a severe form of asthma caused by excess amounts of white blood cells that cause inflammation in the respiratory system. It’s rare and difficult to treat, and requires ...

If you have asthma that’s severe or hard to treat, it may be eosinophilic asthma. Here are some signs: Your symptoms are triggered by something other than allergens. You’re often short of ...

The following is a summary of "Real-world comparison of T2-biologics effectiveness in severe allergic asthma with nasal ...

Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.

The EMA has agreed to review GSK’s application to expand Nucala’s use as an add-on maintenance for individuals with COPD.

Nucala is approved for four indications, namely severe eosinophilic asthma CRSwNP, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES), and has also shown ...

Based on estimates that 5%-10% of asthma patients suffer from severe asthma, that puts the number of eosinophilic asthma sufferers at up to 1.8 million Americans. “As many PPA attendees may have ...

A Prescription Drug User Fee Act target date of December 16, 2025 has been assigned to the application. The Food and Drug Administration (FDA) has accepted for review the Biologics License ...

Remission persisted through 104 weeks for most patients with eosinophilic granulomatosis with polyangiitis who used ...